Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accutane Risk Management Program Changes Held Up By Celgene Patents

This article was originally published in The Pink Sheet Daily

Executive Summary

Four patents relating to the STEPS risk management program for Thalomid are an “obstacle” to implementing an augmented isotretinoin program, FDA says. The agency’s Office of Chief Counsel is reviewing the issue.

You may also be interested in...



FDA Approves "Unprecedented" Risk Management Program For Accutane

Wholesalers, pharmacists, prescribers and patients will have added responsibility under the iPLEDGE program.

FDA Approves "Unprecedented" Risk Management Program For Accutane

Wholesalers, pharmacists, prescribers and patients will have added responsibility under the iPLEDGE program.

Enhanced Isotretinoin Risk Management Plan To Commence In Mid-2005

The program will include central registry for patients, prescribers and dispensing pharmacies, an FDA "Talk Paper" says. Celgene licenses patents covering Thalomid STEPS risk management program to isotretinoin manufacturers.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel